Get started

PFIZER

Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
PFIZER, targeting $50! Upside Prospect ON!PFE weekly data is conveying significant accumulation at the current price range. Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term. The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge. Expect some significant bounce from the current range with initial target to $50. Weekly higher lows on histogram has been registered. Trend shift is about to commence. First Bubble up volume appearance in almost 2 months. Spotted at 38.0 TAYOR Safeguard capital always.
NYSE:PFELong
by JSAL
8
$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences: - Price is in Oversold Conditions in D1 timeframe - Price action bouncing off 150% Fibo Extension - Price is trying to go back above the Interest Zone to give some bullish momentum to the stock Fundamental Confluences: -Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry - They had a good response on a testing of their recent respiratory drug - Value? ---- Health sector in your Portfolio will never be wrong with the global aging population. I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE. Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown. -----
NYSE:PFELong
by weekendanalyst
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points. Disclaimer: This information or service is for informational purposes only and is not intended to be personal financial advice #pfizer
NYSE:PFELong
by sepehr_sanjar
1
Trade Like A Sniper - Episode 16 - Pfizer - (5th June 2024)This video is part of a video series where I backtest a specific asset using the TradingView Replay function, and perform a top-down analysis using ICT's Concepts in order to frame ONE high-probability setup. I choose a random point of time to replay, and begin to work my way down the timeframes. Trading like a sniper is not about entries with no drawdown. It is about careful planning, discipline, and taking your shot at the right time in the best of conditions. A couple of things to note: - I cannot see news events. - I cannot change timeframes without affecting my bias due to higher-timeframe candles revealing its entire range. - I cannot go to a very low timeframe due to the limit in amount of replayed candlesticks In this session I will be analyzing PFE (Pfizer), starting from the 4-Month chart. - R2F
NYSE:PFE
by Road_2_Funded
Pfizer implements $1.5bn cost-cutting initiative. Idea 27/05/24Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has actively restructured its operations, including acquiring cancer drug manufacturer Seagen for 43 billion USD, aiming to diversify and strengthen its product portfolio. Despite these financial adjustments, Pfizer has raised its full-year earnings forecast following better-than-expected earnings in Q1. These results were partly attributed to the successful implementation of cost-saving measures. To bolster its financial standing, the company focuses on operational efficiency, restructuring its network, and enhancing its product portfolio. Given this backdrop, let's examine the potential trading opportunities for Pfizer Inc. (NYSE: PFE): On the Daily (D1) timeframe, Pfizer's stock shows a resistance level at 29.65 USD and support at 28.45 USD. The resistance line of the ongoing downtrend has been breached, suggesting a potential shift in market sentiment. If the trend reverses downward, a possible target might be 25.30 USD. If the current uptrend persists, a short-term target is 31.90 USD upon rebounding from the 29.65 USD resistance level. For a medium-term strategy, the stock price could reach 34.10 USD if the upward momentum continues. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:PFE
by RoboMarkets
Pfizer Wins $107.5 Million From AstraZeneca in US Cancer DrugPfizer ( NYSE:PFE ) has won $107.5 million in damages from AstraZeneca in a US cancer drug patent trial. A Delaware federal jury found that AstraZeneca's lung cancer drug Tagrisso violated its Wyeth unit's patent rights. The jury agreed that AstraZeneca's drug infringed two patents covering methods for treating cancer with the breast-cancer drug Nerlynx, which is sold by Puma Biotechnology. Puma licenses the patents from Pfizer ( NYSE:PFE ) to make its drug. AstraZeneca, which earned AstraZeneca nearly $5.8 billion in revenue last year, denied infringing the patents and argued they are invalid. Pfizer ( NYSE:PFE ) is no longer a plaintiff in the case. A separate bench trial on some of AstraZeneca's remaining defenses is set to be held in June, which could result in a ruling that negates the verdict. Technical Outlook Pfizer ( NYSE:PFE ) closed Friday's trading at $28.64 down by 0.97%. The stock has a Relative Strength Index (RSI) of 64.11 which is liable for further growth. Pfizer ( NYSE:PFE ) stock is set to rise from its Falling Wedge Pattern which started from the 6th of January, 2024.
NYSE:PFE
by DEXWireNews
Pfizer Surges as Earnings Soar Above ExpectationsPfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin. The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and raking in $14.88 billion in revenue, well above the anticipated $13.87 billion. This impressive feat marks a stark turnaround from the previous year's earnings of $1.23 per share on $18.49 billion in sales. Investors reacted positively to Pfizer's optimistic outlook for the year, as the company raised its earnings guidance and maintained its sales forecast. With a projected adjusted profit range of $2.15 to $2.35 per share and sales expected to reach between $58.5 billion and $61.5 billion, Pfizer is poised for a strong fiscal year ahead. Key drivers behind Pfizer's stellar performance include aggressive cost-cutting measures and resilient demand for its COVID-19 products, particularly its vaccine Comirnaty, developed in collaboration with BioNTech. Despite a significant drop in sales of the oral antiviral Paxlovid, which fell 50% to $2.04 billion, Pfizer remains optimistic about the prospects of its COVID portfolio, expecting $8 billion in combined sales from its COVID-19 products. The success of Pfizer's strategic acquisitions, notably the $43 billion deal for Seagen, is evident in the robust sales of cancer treatment Padcev and the continued growth of its pipeline. However, challenges persist, as sales of targeted cancer therapy Adcetris fell short of expectations, underscoring the need for sustained new launch performance. Attention is also focused on Pfizer's RSV vaccine, which has faced stiff competition from a rival shot by GSK. Despite lower-than-anticipated sales of Abrysvo, Pfizer ( NYSE:PFE ) remains committed to advancing its respiratory syncytial virus (RSV) vaccine portfolio. Analysts remain cautiously optimistic about Pfizer's trajectory, with JP Morgan's Chris Schott emphasizing the importance of stronger new launch performance and pipeline progress in reshaping investor sentiment.
NYSE:PFE
by DEXWireNews
FDA Approves Pfizer’s First Gene TherapyIn a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to its debilitating nature and the cumbersome treatment regimens it necessitates. Unveiling Beqvez: Pfizer's newly approved gene therapy, Beqvez, heralds a paradigm shift in hemophilia B treatment. Unlike conventional methods that require frequent infusions of factor IX, Beqvez offers a one-time solution, empowering patients to produce the crucial clotting factor independently. This innovative approach not only promises to alleviate the burden of regular treatments but also holds the potential to prevent and control bleeding more effectively. Transformative Impact: The approval of Beqvez represents a ray of hope for individuals grappling with hemophilia B, offering a lifeline towards improved quality of life and reduced medical complexities. Dr. Adam Cuker, from Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, underscores the transformative potential of Beqvez, emphasizing its ability to mitigate both medical and treatment-related challenges over the long term. Pfizer's Strategic Maneuver For Pfizer ( NYSE:PFE ), the approval of Beqvez marks a strategic triumph in its quest to diversify beyond the realm of COVID therapeutics. With a keen focus on gene and cell therapies, Pfizer ( NYSE:PFE ) is positioning itself at the forefront of medical innovation, aiming to redefine the treatment landscape across various disease domains. The company's investment in Beqvez underscores its commitment to pioneering solutions that address unmet medical needs and enhance patient outcomes. Navigating Challenges: While the approval of Beqvez heralds a new era in hemophilia B treatment, it also presents formidable challenges. The exorbitant price tag of $3.5 million raises concerns about accessibility and affordability, echoing debates surrounding the broader issue of healthcare equity. Furthermore, logistical hurdles and adoption barriers may impede widespread uptake, underscoring the need for comprehensive strategies to ensure equitable access to this groundbreaking therapy. Looking Ahead: As Pfizer ( NYSE:PFE ) embarks on this groundbreaking journey with Beqvez, the company's pipeline continues to brim with promise. From experimental antibodies to gene therapies targeting other genetic disorders like Duchenne muscular dystrophy, Pfizer remains at the vanguard of medical innovation, driving forward the frontier of personalized medicine. As the healthcare landscape evolves, Beqvez stands as a beacon of hope, illuminating a path towards a future where genetic therapies revolutionize the treatment paradigm, one patient at a time.
NYSE:PFELong
by DEXWireNews
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Despite short-term challenges like revenue and earnings declines in the current quarter, Pfizer (PFE) maintains a positive long-term growth trajectory. With optimistic earnings estimates for the full fiscal year, consistent EPS beats, and a discounted valuation relative to peers, Pfizer represents an attractive investment opportunity. Trade Idea: Buy Pfizer (PFE) Long-term growth potential remains strong despite short-term setbacks. Positive earnings outlook for the full fiscal year indicates resilience. Consistent EPS beats highlight Pfizer's ability to manage its bottom line effectively. Discounted valuation compared to industry peers suggests potential for stock price appreciation. Consider a medium to long-term investment horizon to capture Pfizer's growth prospects and maximize returns.
NYSE:PFELong
by Elite_Forex
PFIZER, INC (PFE) 1WOverall Trend: PFIZER, INC (PFE) Downtrend: The price being below the 50, 100, and 200-day moving averages since January 2023 suggests a downtrend. Price Movement: Consolidation: The current price of $25.69 near the 52-week low indicates a possible consolidation phase. Without a one-week chart, it's difficult to say for sure if the price is bouncing off support or continuing the downtrend. Volume: Average Volume: The volume of 64.54 million is around average, which doesn't provide a strong directional signal. Momentum Indicators: RSI (30.00 - 40.00): This indicates oversold territory. Oversold readings don't guarantee an immediate rebound, but they do suggest the stock might be undervalued based on recent price movements. MACD : The MACD signals being below the histogram since January 2023 suggests a downtrend in momentum. This aligns with the price being below the moving averages. Summary: The technical analysis of PFE is mixed. The downtrend, oversold RSI, and MACD below the histogram are bearish indicators. However, the consolidation around the 52-week low and average volume makes it difficult to predict a clear direction in the short term. Here are some additional things to consider: News and Events: Look for any recent news or events that might be impacting the stock price. Fundamental Analysis: Consider factors like PFE's earnings, debt levels, and overall business outlook. Chart Patterns: Analyze the one-week chart for any specific chart patterns that might provide further clues about the stock's direction. Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making any investment decisions. "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy". Tendencia general: Tendencia bajista: El hecho de que el precio esté por debajo de las medias móviles de 50, 100 y 200 días desde enero de 2023 sugiere una tendencia bajista. Movimiento de precios: Consolidación: El precio actual de 25,69 dólares cerca del mínimo de 52 semanas indica una posible fase de consolidación. Sin un gráfico de una semana, es difícil decir con certeza si el precio está rebotando en el soporte o continúa la tendencia bajista. Volumen: Volumen medio: El volumen de 64,54 millones está en torno a la media, lo que no proporciona una señal direccional fuerte. Indicadores de impulso: RSI (30.00 - 40.00): Esto indica territorio de sobreventa. Las lecturas de sobreventa no garantizan un repunte inmediato, pero sí sugieren que las acciones podrían estar infravaloradas en función de los recientes movimientos de precios. MACD: El hecho de que el MACD señale que está por debajo del histograma desde enero de 2023 sugiere una tendencia bajista en el impulso. Esto se alinea con que el precio está por debajo de las medias móviles. Resumen: El análisis técnico de PFE es mixto. La tendencia bajista, el RSI sobrevendido y el MACD por debajo del histograma son indicadores bajistas. Sin embargo, la consolidación en torno al mínimo de 52 semanas y el volumen medio hace que sea difícil predecir una dirección clara a corto plazo. Aquí hay algunas cosas adicionales a considerar: Noticias y eventos: Busque noticias o eventos recientes que puedan estar afectando el precio de las acciones. Análisis fundamental: Considere factores como las ganancias de PFE, los niveles de deuda y las perspectivas generales del negocio. Patrones gráficos: Analice el gráfico de una semana en busca de patrones gráficos específicos que puedan proporcionar más pistas sobre la dirección de la acción. Descargo de responsabilidad: Este análisis es solo para fines informativos y no debe considerarse asesoramiento financiero. Siempre haga su propia investigación antes de tomar cualquier decisión de inversión. "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a acertar nueve de cada diez veces. He descubierto que cuando el mercado está bajando y compras acciones sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar".
NYSE:PFELong
by rodulfox
Pfizer (PFE): Shocking Downward Spiral - $11 Target In Sight?Pfizer (PFE): NYSE:PFE At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation for Pfizer. For the downward movement, we need to examine more closely how far it can actually fall, but $11 is our minimum expectation. The only scenario that would make sense here might be a short position for a possible subordinate Wave (iv) between $36.9 and $41.62. Subsequently, for the overarching Wave ((iii)), we expect another decline to a minimum of $22.64 and, in our opinion, a maximum of $9.56. Entering a long position could be too risky over a longer period. For those looking to trade in the short term, there might be a bottom at $25.61, leading up to the potential target zone for Wave (iv). After that, we expect the downtrend to continue, and personally, we are not positioning ourselves long due to the significant risk.
NYSE:PFEShort
by freeguy_by_wmc
$PFE (Pfizer Inc) - Double Bottom and Missing RetestIt seems like the price may have hit its bottom, as we're seeing two Key Reversals on the Monthly timeframe. This scenario could signal a Double Bottom, setting the stage for a high-probability trade setup with waiting for the price to break through the recent Lower High (LH) to confirm a change in trend. Shifting our focus to the Daily timeframe, there are few potential Sniper Entries opportunities offering the promise of substantial rewards 💸
NYSE:PFELong
by Dragon_Ball
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
Pfizer - Watch The SupportHello Traders, welcome to today's analysis of Pfizer. -------- Explanation of my video analysis: All the way back in 2012 Pfizer created a massively bullish triangle reversal pattern at the $17.00 level. This was followed by a +200% rally. Since 2022 Pfizer has been dropping significantly and is now retesting the support level which I mentioned in the analysis. If we see bullish conformation on the smaller timeframes, this might be an interesting long trading setup. -------- I will only take a trade if all the rules of my strategy are satisfied. Let me know in the comment section below if you have any questions. Keep your long term vision.
NYSE:PFE
by basictradingtv
7